-
Flashpoint Therapeutics Appoints Barry Labinger as CEO
29 Jul 2025 20:22 GMT
… and advanced its lead clinical cancer immunotherapy program into registrational trials … his previous leadership positions at Human Genome Sciences, Bristol Myers Squibb, and Abbott …
-
Flashpoint Therapeutics Appoints Barry Labinger as Chief Executive Officer
28 Jul 2025 22:40 GMT
… of its lead clinical cancer immunotherapy program into registrational … leadership positions, including those at Human Genome Sciences, Bristol Myers Squibb, and … at Immunex, 3M Pharmaceuticals, Human Genome Sciences, Emergent BioSolutions, Bristol Myers …
-
New cell therapy model accelerates cancer treatment development
10 Feb 2025 11:00 GMT
… Resilience + MD Anderson Cancer Center, is transforming cancer treatment with faster, … manufacturing and scaling of innovative cancer therapies. This unique partnership … Anderson, Teva Pharmaceuticals, CoGenesys, and Human Genome Sciences. He earned a BSc in …
-
CAR T Therapy: From Cancer To Autoimmune Disease, The Lupus Example
01 Nov 2022 17:11 GMT
… as applications for B cell cancers and multiple myeloma can be … CAR T therapy as a cancer treatment. A recent study published … . One of our successes at Human Genome Sciences, a company I founded and …
-
Volastra Therapeutics Announces Appointment of David P. Southwell as Chief Executive Officer
27 May 2025 11:19 GMT
Volastra Therapeutics, a clinical-stage cancer biotechnology company, today announced the … executive roles as CFO at Human Genome Sciences through its acquisition by GlaxoSmithKline … approaches to the treatment of cancer by targeting chromosomal instability. …